Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics

Biological Psychiatry

Volumn 72, Issue 11, 2012, Pages 934-942

  Revel, Florent G ^a   Moreau, Jean Luc ^a   Gainetdinov, Raul R ^b   Ferragud, Antonio ^c   Velázquez Sánchez, Clara ^c   Sotnikova, Tatyana D ^b   Morairty, Stephen R ^d   Harmeier, Anja ^a   Groebke Zbinden, Katrin ^a   Norcross, Roger D ^a   Bradaia, Amyaouch ^e   Kilduff, Thomas S ^d   Biemans, Barbara ^a   Pouzet, Bruno ^a   Caron, Marc G ^f   Canales, Juan J ^c   Wallace, Tanya L ^a,d   Wettstein, Joseph G ^a   Hoener, Marius C ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c UNIVERSITY OF CANTERBURY   (New Zealand)

^d SRI INTERNATIONAL   (United States)

^e Neuroservice   (France)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anxiety; cocaine self administration; cognition; depression; schizophrenia; sleep wake

Indexed keywords

4 (3,4 DICHLOROPHENYL) 4,5 DIHYDROOXAZOL 2 YLAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; G PROTEIN COUPLED RECEPTOR; NEUROLEPTIC AGENT; RO 5203648; TRACE AMINE ASSOCIATED RECEPTOR 1; UNCLASSIFIED DRUG;

ALERTNESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; ATTENTION; BRAIN SLICE; CATALEPSY; CENTRAL NERVOUS SYSTEM DISEASE; COCAINE DEPENDENCE; COGNITION; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC ACTIVITY; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; HAPLORHINI; MONOAMINE NERVE CELL; MOUSE; NONHUMAN; PHYSICOCHEMICAL MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROTONINERGIC NERVE CELL; TRANQUILIZING ACTIVITY; VENTRAL TEGMENTUM; WAKEFULNESS;

ACTION POTENTIALS; ANIMALS; DOPAMINERGIC NEURONS; MICE; MOTOR ACTIVITY; OXAZOLES; RAPHE NUCLEI; RECEPTORS, G-PROTEIN-COUPLED; SEROTONERGIC NEURONS; VENTRAL TEGMENTAL AREA;

EID: 84868195010     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.05.014     Document Type: Article

References (62)

1. S.A. Burchett, T.P. Hicks The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain Prog Neurobiol 79 2006 223 246
2. D.K. Grandy Trace amine-associated receptor 1-Family archetype or iconoclast? Pharmacol Ther 116 2007 355 390
3. M.D. Berry The potential of trace amines and their receptors for treating neurological and psychiatric diseases Rev Recent Clin Trials 2 2007 3 19
4. B. Borowsky, N. Adham, K.A. Jones, R. Raddatz, R. Artymyshyn, K.L. Ogozalek Trace amines: Identification of a family of mammalian G protein-coupled receptors Proc Natl Acad Sci U S A 98 2001 8966 8971
5. J.R. Bunzow, M.S. Sonders, S. Arttamangkul, L.M. Harrison, G. Zhang, D.I. Quigley Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor Mol Pharmacol 60 2001 1181 1188
6. L. Lindemann, M. Ebeling, N.A. Kratochwil, J.R. Bunzow, D.K. Grandy, M.C. Hoener Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors Genomics 85 2005 372 385
7. L. Lindemann, M.C. Hoener A renaissance in trace amines inspired by a novel GPCR family Trends Pharmacol Sci 26 2005 274 281
8. T.D. Sotnikova, M.G. Caron, R.R. Gainetdinov Trace amine-associated receptors as emerging therapeutic targets Mol Pharmacol 76 2009 229 235
9. L. Lindemann, C.A. Meyer, K. Jeanneau, A. Bradaia, L. Ozmen, H. Bluethmann Trace amine-associated receptor 1 modulates dopaminergic activity J Pharmacol Exp Ther 324 2008 948 956
10. T.D. Wolinsky, C.J. Swanson, K.E. Smith, H. Zhong, B. Borowsky, P. Seeman The Trace Amine 1 receptor knockout mouse: An animal model with relevance to schizophrenia Genes Brain Behav 6 2007 628 639
11. F.G. Revel, J.L. Moreau, R.R. Gainetdinov, A. Bradaia, T.D. Sotnikova, R. Mory TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity Proc Natl Acad Sci U S A 108 2011 8485 8490
12. A. Bradaia, G. Trube, H. Stalder, R.D. Norcross, L. Ozmen, J.G. Wettstein The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system Proc Natl Acad Sci U S A 106 2009 20081 20086
13. G.M. Miller The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity J Neurochem 116 2011 164 176
14. Z. Xie, G.M. Miller Trace amine-associated receptor 1 is a modulator of the dopamine transporter J Pharmacol Exp Ther 321 2007 128 136
15. H.N. Panas, L.J. Lynch, E.J. Vallender, Z. Xie, G.L. Chen, S.K. Lynn Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice J Neurosci Res 88 2010 1962 1969
16. T.S. Scanlan, K.L. Suchland, M.E. Hart, G. Chiellini, Y. Huang, P.J. Kruzich 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone Nat Med 10 2004 638 642
17. T.D. Sotnikova, J.M. Beaulieu, S. Espinoza, B. Masri, X. Zhang, A. Salahpour The dopamine metabolite 3-methoxytyramine is a neuromodulator PLoS ONE 5 2010 e13452
18. T.M. Ballard, F. Knoflach, E. Prinssen, E. Borroni, J.A. Vivian, J. Basile RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors Psychopharmacology (Berl) 202 2009 207 223
19. K. Rutten, J.L. Basile, J. Prickaerts, A. Blokland, J.A. Vivian Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques Psychopharmacology (Berl) 196 2008 643 648
20. C. Velazquez-Sanchez, A. Ferragud, V. Hernandez-Rabaza, A. Nacher, V. Merino, M. Carda The dopamine uptake inhibitor 3 alpha-[bis(4'-fluorophenyl) metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward Neuropsychopharmacology 34 2009 2497 2507
21. S.R. Morairty, L. Hedley, J. Flores, R. Martin, T.S. Kilduff Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats Sleep 31 2008 34 44
22. R.R. Gainetdinov, A.R. Mohn, M.G. Caron Genetic animal models: Focus on schizophrenia Trends Neurosci 24 2001 527 533
23. B. Giros, M. Jaber, S.R. Jones, R.M. Wightman, M.G. Caron Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter Nature 379 1996 606 612
24. D. Boulay, O. Bergis, P. Avenet, G. Griebel The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice Neuropsychopharmacology 35 2010 416 427
25. D. Alberati, J.L. Moreau, R. Mory, E. Pinard, J.G. Wettstein Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential Pharmacol Biochem Behav 97 2010 185 191
26. A.R. Mohn, R.R. Gainetdinov, M.G. Caron, B.H. Koller Mice with reduced NMDA receptor expression display behaviors related to schizophrenia Cell 98 1999 427 436
27. D.E. Casey Tardive dyskinesia and atypical antipsychotic drugs Schizophr Res 35 suppl 1999 S61 S66
28. P.R. Sanberg, M.D. Bunsey, M. Giordano, A.B. Norman The catalepsy test: Its ups and downs Behav Neurosci 102 1988 748 759
29. M.L. Wadenberg, A. Soliman, S.C. VanderSpek, S. Kapur Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects Neuropsychopharmacology 25 2001 633 641
30. G. Lucas, N. Bonhomme, P. De Deurwaerdere, M. Le Moal, U. Spampinato 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release Psychopharmacology (Berl) 131 1997 57 63
31. T.R. Insel Rethinking schizophrenia Nature 468 2010 187 193
32. T.W. Robbins, A.C. Roberts Differential regulation of fronto-executive function by the monoamines and acetylcholine Cereb Cortex 17 Suppl 1 2007 i151 i160
33. J.D. Jentsch, J.R. Taylor, J.D. Elsworth, D.E. Redmond Jr, R.H. Roth Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits Neuroscience 90 1999 823 832
34. O. Berton, E.J. Nestler New approaches to antidepressant drug discovery: Beyond monoamines Nat Rev Neurosci 7 2006 137 151
35. G.J. Marek Serotonin and dopamine interactions in rodents and primates: Implications for psychosis and antipsychotic drug development Int Rev Neurobiol 78 2007 165 192
36. S.P. Singh, V. Singh, N. Kar, K. Chan Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis Br J Psychiatry 197 2010 174 179
37. J.F. Cryan, C. Mombereau In search of a depressed mouse: Utility of models for studying depression-related behavior in genetically modified mice Mol Psychiatry 9 2004 326 357
38. J.M. O'Donnell, G.J. Marek, L.S. Seiden Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule Neurosci Biobehav Rev 29 2005 785 798
39. J.A. Bouwknecht, B. Olivier, R.E. Paylor The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: A review of pharmacological and genetic studies in the mouse Neurosci Biobehav Rev 31 2007 41 59
40. S.E. Hyman, R.C. Malenka, E.J. Nestler Neural mechanisms of addiction: The role of reward-related learning and memory Annu Rev Neurosci 29 2006 565 598
41. L.V. Panlilio, S.R. Goldberg Self-administration of drugs in animals and humans as a model and an investigative tool Addiction 102 2007 1863 1870
42. K. Wulff, S. Gatti, J.G. Wettstein, R.G. Foster Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease Nat Rev Neurosci 11 2010 589 599
43. H.E. Shannon, E.J. Cone, D. Yousefnejad Physiologic effects and plasma kinetics of beta-phenylethylamine and its N-methyl homolog in the dog J Pharmacol Exp Ther 223 1982 190 196
44. J.D. Urban, W.P. Clarke, M. von Zastrow, D.E. Nichols, B. Kobilka, H. Weinstein Functional selectivity and classical concepts of quantitative pharmacology J Pharmacol Exp Ther 320 2007 1 13
45. S. Rajagopal, K. Rajagopal, R.J. Lefkowitz Teaching old receptors new tricks: Biasing seven-transmembrane receptors Nat Rev Drug Discov 9 2010 373 386
46. K. Fuxe, M. Canals, M. Torvinen, D. Marcellino, A. Terasmaa, S. Genedani Intramembrane receptor-receptor interactions: A novel principle in molecular medicine J Neural Transm 114 2007 49 75
47. R. Maggio, F. Novi, M. Scarselli, G.U. Corsini The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology FEBS J 272 2005 2939 2946
48. R.B. Mailman, V. Murthy Third generation antipsychotic drugs: Partial agonism or receptor functional selectivity? Curr Pharm Des 16 2010 488 501
49. S.M. Stahl Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors J Clin Psychiatry 62 2001 841 842
50. M.L. Carlsson, A. Carlsson, M. Nilsson Schizophrenia: From dopamine to glutamate and back Curr Med Chem 11 2004 267 277
51. S. Espinoza, A. Salahpour, B. Masri, T.D. Sotnikova, M. Messa, L.S. Barak Functional interaction between Trace Amine Associated Receptor 1 (TAAR1) and dopamine D2 receptor Mol Pharmacol 80 2011 416 425
52. G.F. Koob, H.T. Le, I. Creese The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat Neurosci Lett 79 1987 315 320
53. S.S. Negus, N.K. Mello, X. Lamas, J.H. Mendelson Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys J Pharmacol Exp Ther 278 1996 879 890
54. B.A. Davis, A.A. Boulton The trace amines and their acidic metabolites in depression - an overview Prog Neuropsychopharmacol Biol Psychiatry 18 1994 17 45
55. H.C. Sabelli, J.I. Javaid Phenylethylamine modulation of affect: Therapeutic and diagnostic implications J Neuropsychiatry Clin Neurosci 7 1995 6 14
56. H. Sabelli, P. Fink, J. Fawcett, C. Tom Sustained antidepressant effect of PEA replacement J Neuropsychiatry Clin Neurosci 8 1996 168 171
57. H.C. Sabelli, J. Fawcett, F. Gusovsky, J. Javaid, J. Edwards, H. Jeffriess Urinary phenyl acetate: A diagnostic test for depression? Science 220 1983 1187 1188
58. H.C. Sabelli, J. Fawcett, F. Gusovsky, J.I. Javaid, P. Wynn, J. Edwards Clinical studies on the phenylethylamine hypothesis of affective disorder: Urine and blood phenylacetic acid and phenylalanine dietary supplements J Clin Psychiatry 47 1986 66 70
59. J. Grimsby, M. Toth, K. Chen, T. Kumazawa, L. Klaidman, J.D. Adams Increased stress response and beta-phenylethylamine in MAOB-deficient mice Nat Genet 17 1997 206 210
60. M. Bortolato, S.C. Godar, S. Davarian, K. Chen, J.C. Shih Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice Neuropsychopharmacology 34 2009 2746 2757
61. E.M. Demet, A. Chicz-Demet, J.H. Fallon, K.N. Sokolski Sleep deprivation therapy in depressive illness and Parkinson's disease Prog Neuropsychopharmacol Biol Psychiatry 23 1999 753 784
62. H. Giedke, F. Schwarzler Therapeutic use of sleep deprivation in depression Sleep Med Rev 6 2002 361 377